The Effectiveness & Safety of 4% Sodium Citrate as a Lock Solution in

Status Enrolling by invitation

Clinical Trial Summary

Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. This study will compare effectiveness and safety utilizing 4% sodium citrate vs. heparin as a lock solution in central venous hemodialysis catheter among hemodialysis patients.

Clinical Trial Description

Vascular access is necessary for hemodialysis(HD) procedure. In normal situation, vascular access for HD is created in peripheral vessels. However, vascular catheter may be considered in patients without available peripheral vessels for vascular access. The characteristic of these patients include elderly, diabetes, not tolerant to vascular surgery etc.. Commonly, the HD catheter is inserted in the central vein in these population. Considering clotting condition, anticoagulant is indicated for catheter locking after HD session. In the past years, heparin is the most common solution to be used as locking solution. Nevertheless, heparin has a few disadvantages, such as systemic anticoagulation, thrombocytopenia, and bleeding risk. An alternative for anticoagulation in HD session is 4% sodium citrate. The effectiveness and safety of sodium citrate in HD sessions have been reported in clinical studies. Characteristics of sodium citrate and safety profile Trisodium citrate acts locally as an anticoagulant by chelating ionized calcium in blood, resulting in the blockage of calcium-dependent clotting pathways. Studies that used a dilute citrate formulation (4%) demonstrated efficacy as an anticoagulant with minimal to no risk of bleeding in HD sessions. The advantageous effects of sodium citrate in HD catheter locking solution includes reducing frequency of catheter exchanges, reducing using of thrombolytic drugs, reducing hospitalization rates, and bacteremia. Regarding adverse effect of sodium citrate, hypocalcemia and other untoward outcomes are rare reported in the previous clinical studies ;

Study Design

Related Conditions & MeSH terms

Central Venous Catheter Thrombosis
Renal Dialysis
Thrombosis
Upper Extremity Deep Vein Thrombosis

Clinical Trial Details

NCT number	NCT05188339
Study type	Interventional
Source	Chang Gung Memorial Hospital
Contact
Status	Enrolling by invitation
Phase	Phase 2/Phase 3
Start date	July 20, 2022
Completion date	December 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05189795` - The Construction of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients
Completed	`NCT01125202` - Intervention to Reduce Dietary Sodium in Hemodialysis	N/A
Completed	`NCT00730145` - A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis	Phase 1
Completed	`NCT00753116` - Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension	Phase 1
Completed	`NCT00806130` - Health Related Quality of Life and Cognitive Function Among Norwegian Dialysis Patients
Completed	`NCT05718765` - The Effect of Physical ACtivity Enhancement Scheme (PACES) in Hemodialysis Patients	N/A
Completed	`NCT03250715` - Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure	N/A
Completed	`NCT05469620` - Adaptive Nutrition Therapy in Hemodialysis	N/A
Completed	`NCT03536858` - Social Networks and Renal Education: Promoting Transplantation	N/A
Completed	`NCT00824837` - Study of beta2-Microglobulin Removal by Standard Versus New High Cut-Off Haemodialysis Membrane	Phase 1/Phase 2
Completed	`NCT03403491` - Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis	N/A
Terminated	`NCT02495662` - The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation	Phase 2
Completed	`NCT01179620` - Certoparin in Renal Patients Undergoing Hemodialysis	Phase 3
Completed	`NCT01017276` - A Phase 3 Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Peritoneal Dialysis	Phase 3
Active, not recruiting	`NCT04466865` - A Communication Tool to Assist Older Adults Facing Dialysis Choices	N/A
Recruiting	`NCT03782519` - Quality of Life of Frail Aged Patients in Incremental Hemodialysis	N/A
Recruiting	`NCT02843334` - Study of the Prevalence of Fabry Disease in French Dialysis Patients	N/A
Recruiting	`NCT02545530` - Transdermal Clonidine in Chronic Hemodialysis Patients	N/A
Completed	`NCT00892749` - Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis	Phase 3
Completed	`NCT00649298` - A Clinical Trial of IntensiVE Dialysis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The Effectiveness and Safety of 4% Sodium Citrate as a Lock Solution in Central Venous Hemodialysis Catheter

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms